Introduction
============

A significant proportion (15--20%) of patients with lung adenocarcinoma harbor epidermal growth factor receptor (*EGFR*) activating mutations ([@b1-ol-0-0-6913]) and can benefit from first-line treatment with tyrosine kinase inhibitors (TKI), including gefitinib ([@b2-ol-0-0-6913]) or erlotinib ([@b3-ol-0-0-6913]) (first generation TKI) and afatinib (second generation TKI) ([@b4-ol-0-0-6913]). However, after 12--16 months of TKI treatment almost all patients develop acquired resistance and experience tumour progression ([@b5-ol-0-0-6913],[@b6-ol-0-0-6913]).

The most common resistance mechanism, detectable in \~50% of TKI resistant tumors, is the emergence of a secondary T790M mutation in exon 20 of *EGFR* ([@b5-ol-0-0-6913],[@b7-ol-0-0-6913]). Other well-known resistance mechanisms, in patients with non-small cell lung cancer treated with EGFR-TKI, include the amplification of *MET* proto-oncogene tyrosine kinase receptor (*MET*) (20%) ([@b8-ol-0-0-6913]), the development of small cell lung cancer transformation (14%) ([@b9-ol-0-0-6913],[@b10-ol-0-0-6913]) and the presence of acquired phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (*PI3KCA*) mutations (5%) ([@b6-ol-0-0-6913]). Less common resistance mechanisms (30%) include the activation of Insulin-Like Growth Factor-1 Receptor ([@b11-ol-0-0-6913]), the epithelial to mesenchymal transition ([@b12-ol-0-0-6913]), and more rarely squamous cell transformation ([@b13-ol-0-0-6913]--[@b16-ol-0-0-6913]). Different resistance mechanisms may be observed in the same patient ([@b6-ol-0-0-6913]) due to intratumor and intrametastatic heterogeneity ([@b17-ol-0-0-6913]), which strongly influence the patient\'s response to treatment.

The identification of molecular alterations responsible for acquired TKI resistance is crucial for patient management, as multiple novel treatment strategies are available to overcome this issue ([@b18-ol-0-0-6913]). For instance, in cases of T790M-mediated resistance, the use of a third-generation TKI, which irreversibly and selectively blocks T790M mutant clones, has been demonstrated to increase the potency of EGFR-TK inhibition ([@b19-ol-0-0-6913],[@b20-ol-0-0-6913]).

A second tumour biopsy is recommended in case of TKI resistance; however, a single biopsy specimen may not mirror all the biological properties of a tumour. Combining re-biopsy analysis with molecular characterization of circulating cell-free tumour (ct) DNA represents a good strategy to describe the molecular landscape of a tumour ([@b21-ol-0-0-6913]--[@b23-ol-0-0-6913]). In addition, temporal changes to *EGFR* activating and resistance mutations in plasma DNA are directly linked to treatment efficacy ([@b24-ol-0-0-6913],[@b25-ol-0-0-6913]).

In the present report the case of a patient who developed two resistance mechanisms in response to first-line afatinib, the T790M mutation and the rare squamous cell transformation, is described. To the best of our knowledge, only a few similar cases have previously been described and they focused on patients with lung adenocarcinoma who were treated with erlotinib and gefitinib ([@b13-ol-0-0-6913]--[@b15-ol-0-0-6913]).

Case report
===========

Written informed consent for the publication of this report was obtained from the patient. In October 2014, a 44-year-old female with an 8 pack/year smoking history presented at the University Hospital of Pisa (Pisa, Italy) with back pain. A few weeks later the patient underwent magnetic resonance imaging of the vertebral column, which revealed a number of osteoblastic bone lesions (S1-3; D2-3 and D7-10 laminas). A computed tomography (CT) scan revealed a left lower lobe mass, and pleural and pericardial effusions (PE). The patient underwent endobronchial ultrasound biopsy and pleural fluid analyses. Histological and cytological samples examination identified an adenocarcinoma, further characterized using cell-block (stained with 10% buffered formalin at room temperature for 24 h) paraffin-embedded sections (thickness, 2 µm) by immunohistochemical staining using the ultraView Universal DAB Detection kit (Ventana Medical Systems. Inc., Tucson, AZ, USA), according to the manufacturer\'s protocol, with anti-thyroid transcription factor (TTF-1) antibody (mouse monoclonal primary antibody; clone 8G7G3/1; ready-to-use; catalog no. 790-438; Ventana Medical Systems, Inc.) for 44 min at 37°C, which demonstrated a strong positive nuclear stain. An Olympus BX51 light microscope (Olympus Italia Srl; Segrate, Italy) was used for the analysis. The final diagnosis was adenocarcinoma ([@b26-ol-0-0-6913]), consistent with a lung primary cancer with bone metastases.

An extensive molecular analysis was performed on the PE. Fluorescent *In Situ* Hybridization (FISH) was performed to evaluate translocations of anaplastic lymphoma kinase (*ALK*) (using a Vysis ALK Dual-Color Break Apart FISH probe kit; Abbott Laboratories, Abbott Park, IL, USA), proto-oncogene tyrosine-protein kinase ROS (*ROS1*; using a *ROS1* 6q22 Break Probe; Kreatech; Leica Microsystems, Ltd., Milton Keynes, UK) and *RET* proto-oncogene (*RET*; using a *RET* 10q11 Break Probe; Kreatech; Leica Microsystems, Ltd.), and to assess the presence of *MET* amplification (Vysis MET Spectrum Red and CEP7 D7Z1 Spectrum Green; Abbott Laboratories). FISH analysis was performed according to the manufacturers\'protocols. All FISH tests were negative: *ALK*, 4% of neoplastic rearranged cells (cut-off 15%); *ROS1*, 0% of neoplastic rearranged cells (cut-off 15%); *RET*, 5% of neoplastic rearranged cells (cut-off 15%); and *MET*, MET/CEP7=1,1 (cut-off ≥2).

Mutational analysis of *KRAS, BRAF, NRAS, PIK3CA, ALK, ERBB2, DDR2, MAP2K1, EGFR, RET* was performed using a Sequenom Mass-Array (matrix assisted laser desorption ionization-time of flight mass spectrometry) using the Myriapod Lung Status kit (Diatech Pharmacogenetics SRL, Jesi, Italy) together with the analysis software MASSARRAY^®^ TYPER 4.0 (Diatech Pharmacogenetics, Jesi SRL) according to the manufacturer\'s protocol (limit of detection: 2.5--5% for EGFR and 2.5--10% for all other genes). The PE demonstrated a deletion in *EGFR* exon 19 (ex19del).

In November 2014, the patient started treatment with afatinib (40 mg/day, orally). The bone lesions required a radio therapeutic approach due to nerve peduncle compression, therefore the patient received radiation (30 Gy in five fractions on S1-3; 25 Gy in five fractions on D7-10 and 30 Gy in five fractions on D2-3). In addition, the patient was treated with denosumab (120 mg every 28 days, intravenously). After 4 weeks of afatinib, a CT scan revealed a partial response in the lung mass, and a total response for the effusions and bone lesions.

The patient tolerated the therapy well, with mild diarrhea and post-actinic pneumonia, which was treated with antibiotics and anti-inflammatory therapy. Foci of post-actinic pneumonia were observed, primarily on paravetebral and medium lobe sites. At subsequent medical examinations, after 5, 7 and 9 months of treatment, the patient was stable and no *EGFR* mutations were detected on ctDNA from plasma collected at each visit ([Fig. 1A](#f1-ol-0-0-6913){ref-type="fig"}). ctDNA was purified from 4 ml of plasma using a QIAmp Circulating Nucleic Acid kit (Qiagen, Inc., Valencia, CA, USA) and *EGFR* mutational analysis was performed using an Easy^®^EGFR Quantitative Real Time PCR kit (Diatech Pharmacogenetics SRL) according to the manufacturer\'s protocol. The Easy^®^EGFR quantitative Real Time PCR kit is validated for use on liquid biopsy and its limit of detection ranges from 0.5 to 2%.

In February 2016, a CT scan control detected an almost complete response on the primitive lung mass and bone lesions. The patient carried on the therapy with afatinib and denosumab. Three months later (May 2016), a CT scan demonstrated a large area of atelectasia of the upper left lung lobe partially involving the lower lobe with PE. The cytological examination of PE confirmed an adenocarcinoma with a positive immunohistochemical stain for TTF-1. Cytological samples from pleural effusion were positive for *EGFR* ex19del and T790M; both mutations were concomitantly detected in ctDNA ([Fig. 1B](#f1-ol-0-0-6913){ref-type="fig"}). Broncospic investigation of the upper left bronchus revealed a partial obstruction and infiltration from a whitish neoformation. This lesion was biopsied. The obtained tissue was fixed in 10% buffered formalin (room temperature, 24 h), paraffin-embedded and cut into 5 µm thick sections. The hematoxylin-eosin stain (room temperature, 1 h 26 min) revealed a keratinizing squamous cell carcinoma confirmed by immunohistochemical examination, performed as aforementioned, using a p40 antibody (mouse monoclonal primary antibody; clone BC28; ready-to-use; catalog no. 790-4950; Ventana Medical System, Tucson, AZ, USA) for 40 min at 42°C, the results of which were strongly positive, and for TTF-1 antibody, the result of which was negative. The two lesions harboured the ex19del mutation. The same FISH and mutational tests as those executed on pre-TKI specimen were performed on the post-TKI adenocarcinoma and squamous cell carcinoma samples. Again, all FISH tests gave negative results: *ALK*, 0% of neoplastic rearranged cells; *ROS1*, 0% of neoplastic rearranged cells; *RET*, 0% of neoplastic rearranged cells; and *MET*, MET/CEP7=1 in the adenocarcinoma. In the squamous cell carcinoma: *ALK*, 2% of neoplastic rearranged cells; *ROS1*, 0% of neoplastic rearranged cells; *RET*, 0% of neoplastic rearranged cells; and *MET*, MET/CEP7=1. In addition, *HER2* amplification (Vysis HER-2/neu SpectrumOrange/CEP17 SpectrumGreen Probes; Abbott Laboratories) was evaluated in post-TKI samples, for which the results were negative: HER2/CEP17=0.9 (cut-off ≥2) in the adenocarcinoma, HER2/CEP17=1 (cut-off ≥2) in the squamous cell carcinoma.

The patient underwent osimertinib (80 mg/day, orally) therapy and radiotherapy for squamous lesions. At a 2-month follow-up T790M positive lesions exhibited a partial regression. [Fig. 2](#f2-ol-0-0-6913){ref-type="fig"} presents the patient\'s CT-images and histological examinations, and [Fig. 3](#f3-ol-0-0-6913){ref-type="fig"} presents the patient\'s clinical response.

Discussion
==========

Patients with *EGFR* mutant lung adenocarcinoma treated with TKI typically develop resistance within 1 year of treatment ([@b5-ol-0-0-6913]). The existence of different acquired TKI resistance mechanisms together with tumour heterogeneity constitutes a major challenge for clinical practice ([@b6-ol-0-0-6913]).

The present report describes the case of a patient with lung adenocarcinoma treated with afatinib who developed the T790M mutation and squamous cell transformation. To date, only a few cases of squamous cell transformation, with ([@b13-ol-0-0-6913],[@b15-ol-0-0-6913]) and without ([@b14-ol-0-0-6913]) concomitant T790M, have been reported in response to erlotinib and gefitinib, and no similar cases have been reported in response to afatinib ([@b27-ol-0-0-6913]). Longo *et al* ([@b16-ol-0-0-6913]) recently reported a case of lung cell adenocarcinoma positive for the *EGFR* exon 21 L858R mutation, who, following TKI treatment, developed squamous cell carcinoma change together with an *EGFR* exon 20 S768I secondary mutation.

In our case, histological transformation may have been a consequence of TKI treatment or it could have been enhanced by radiotherapy, as reported in other types of cancer, including prostate cancer ([@b28-ol-0-0-6913]).

All the histological evaluations have been performed on specimens obtained by needle biopsy, and although there were different morphological and immunohistochemical characteristics in pre and post-TKI lesions, the presence of the squamous cell carcinoma prior to EGFR-TKI therapy in form of an adenosquamous carcinoma cannot be excluded. However, lung adenocarcinoma exhibits a different molecular landscape compared with squamous cell carcinoma, for instance *EGFR* mutations are present in 10--40% of cases of adenocarcinoma, but rarely in squamous cell carcinoma ([@b29-ol-0-0-6913]). The presence of ex19del in both lesions in the present study suggests that the adenocarcinoma and squamous carcinoma components share the same clonal origin and a mixed tumour is unlikely on the basis of the different location of the two lesions. Furthermore, all the tumour lesions were extensively characterized from a molecular point of view and the only difference was the presence of the T790M mutation, which was detected only in the post-TKI adenocarcinoma specimen.

The reported case highlights the role of intra-tumour heterogeneity, defined as the presence within the same tumour of distinct cellular populations with specific phenotypic features, in response to TKI treatment, which selects clones with intrinsic or acquired resistance that drive disease progression ([@b30-ol-0-0-6913]--[@b32-ol-0-0-6913]). However, a complete characterization of the mechanisms of response and resistance is essential to provide patients with the greatest clinical benefit and several studies and case reports confirm this issue ([@b5-ol-0-0-6913],[@b6-ol-0-0-6913],[@b9-ol-0-0-6913],[@b10-ol-0-0-6913],[@b13-ol-0-0-6913]--[@b16-ol-0-0-6913],[@b18-ol-0-0-6913]).

In the present context, a single tumour biopsy, limited by the presence of geographic heterogeneity, may be inadequate to detect all cancer gene mutations, explaining the lack of a direct correlation between molecular alteration and clinical efficacy of treatment ([@b23-ol-0-0-6913]). The liquid biopsy and analysis of ctDNA furthers understanding of intra-tumour heterogeneity, since it detects contributions from multiple tumour sites. In the present case report, as soon as the patient experienced clinical progression, activating and resistance mutations became detectable on ctDNA, supporting its value in agreement with previously published data ([@b24-ol-0-0-6913],[@b25-ol-0-0-6913]).

However, according to current knowledge and reported cases, neither liquid biopsy nor solid biopsy on their own can suffice for the monitoring of cancer therapy. In spite of the non-invasiveness of liquid biopsy and its high informative value, resistance mechanisms, including phenotypic changes, cannot be evaluated without a histopathological analysis of tumour tissues; for this reason tissue biopsy should be performed whenever possible.

In conclusion, the present case report underlines the complementarity of tumour re-biopsies and analysis of ctDNA in order to have a more complete view of temporal evolution and molecular diversity of TKI-resistant disease, thus improving therapeutic regimens.

![*EGFR* molecular analysis on ctDNA. Graphs from the quantitative polymerase chain reaction showing *EGFR* molecular analysis on ctDNA after (A) 9 and (B) 16 months of treatment with afatinib. Black curve: Control mix, including primers and probe for a non-polymorphic *EGFR* region. The amplification of the control region allows for the evaluation of ctDNA quality and quantity. Green curve: ex19del mix, including primers and probe for 21 types of *EGFR* deletions. Blue curve: T790M mix, including primers and probe for *EGFR* T790M mutation. *EGFR*, epidermal growth factor receptor; ctDNA, circulating cell-free tumour DNA.](ol-14-05-5947-g00){#f1-ol-0-0-6913}

![CT images and histological examinations of the patient. (A) CT image of patient at the time of diagnosis; (B and C) CT images of patient at the time of progression. (D) Pre-afatinib treatment of original adenocarcinoma in pleural effusion (hematoxylin and eosin, magnification, ×200); (E) TTF-1 positive stain. (F) Post-afatinib treatment adenocarcinoma in pleural effusion (hematoxylin and eosin). (G) TTF-1 positive stain. (H) Post-afatinib squamous cell transformation in core needle biopsy of the upper left bronchus (hematoxylin and eosin); (I) p40 positive stain. Scale bar, 100 µm. Magnification for histochemical staining images, ×200. CT, computed tomography; TTF-1, thyroid transcription factor-1.](ol-14-05-5947-g01){#f2-ol-0-0-6913}

![Diagram illustrating the longitudinal and clinical evaluation of the patient. Target dependent, lesions responding to afatinib treatment (epidermal growth factor receptor positive) (LLL and pleural effusion); target independent, lesions resistant to afatinib treatment \[LUL (squamous cell carcinoma)\]. LLL, left lower lobe; LUL, left upper lobe.](ol-14-05-5947-g02){#f3-ol-0-0-6913}
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